In a 3-nitropropionic acid animal model of Huntington’s disease (HD), RES derivatives delayed the onset and reduced the severity of HD-like symptoms, improved locomotor activity, and protected against weight loss, with simultaneous enhancement of superoxide dismutase 2 (SOD2) expression in brain tissue and a decrease in circulating levels of interleukin-6 (IL-6), respectively [51]. The gene discussed is SOD2; the disease is Huntington disease.